C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1)
Authors:
- 5 February 2021
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 402 (6) , 729-737
Abstract
Strategies to sensitize hepatocellular carcinomas (HCC) to programmed death-1 (PD1)/programmed death-ligand 1 (PD-L1) inhibitor therapies are important in improving the survival of HCC patients. The aim of the study was to characterize C-X-C chemokine receptor 2 (Cxcr2) as a therapeutic target in HCC and evaluate the effects of Cxcr2 suppression in sensitizing HCC to PD1/PD-L1 inhibitor therapies. To this end, we constructed a Cxcr2-knockout HCC cell line (Hepa1-6 KO) using the CRISPR-Cas9 approach and assessed the tumor growth rate and survival of mice after subcutaneously inoculating Hepa1-6 KO cells in mice. We show that Cxcr2 knockdown does not dramatically inhibit tumor growth and improve mouse survival. In tumor xenografts, the proportion of T cells is not affected but the ratio of M1/M2 macrophage is greatly increased. Cxcr2 knockdown does not alter cell viability but macrophages co-cultured with Hepa1-6 KO cells are shifted to M1 phenotypes compared to WT cells. Hepa-1-6 KO cells exhibit lower levels of PD-L1 expression. c-Myc is suppressed in Hepa1-6 KO cells, which contributes to PD-L1 downregulation. Knockdown of Cxcr2 decreases PD-L1 levels and consequently promotes the shift of macrophages to the M1 phenotype, which is mediated by downregulating c-Myc. In summary, Cxcr2 is a potential target for suppressing immune escape in HCC.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LY21H160016)
- Hangzhou Social Development Project of Science and Technology Commission (20180533B34)
- Medicine and Health Science and Technology Plan Projects of Zhejiang Province (2021KY231)
This publication has 27 references indexed in Scilit:
- Loco-regional treatment of HCC: current statusClinical Radiology, 2017
- Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinomaJournal of Biological Chemistry, 2017
- miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinomaOncoTargets and Therapy, 2017
- miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular CarcinomaBioMed Research International, 2016
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological featuresHepatology, 2016
- MYC regulates the antitumor immune response through CD47 and PD-L1Science, 2016
- CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinomaJournal of Experimental & Clinical Cancer Research, 2015
- TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progressionOncotarget, 2015
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 EfficacyScience Translational Medicine, 2014
- Enhanced Expression and Clinical Significance of Chemokine Receptor CXCR2 in Hepatocellular CarcinomaJournal of Surgical Research, 2011